Oruka Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Oruka Therapeutics
Pharmaceutical Preparations, SIC 2834
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapies for chronic skin and inflammatory conditions. Its development pipeline targets validated biological pathways to treat diseases such as psoriasis, psoriatic arthritis, and hidradenitis suppurativa. The company's lead investigational drug candidates include ORKA-001, an extended half-life antibody targeting interleukin-23p19, and ORKA-002, an extended half-life antibody targeting interleukin-17A and interleukin-17F. These therapeutics are designed to serve patients suffering from autoimmune and inflammatory disorders.
The company operates in the biotechnology and pharmaceutical sector with ongoing clinical-stage trials, including studies conducted in human patients and healthy volunteers. Oruka Therapeutics, Inc. maintains its principal executive offices and corporate headquarters in Menlo Park, California.
Summary of the business section of Oruka Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Oruka Therapeutics, Inc.
- Founded
- 2024
- Headquarters
- Menlo Park, CA
- Address
- 855 Oak Grove Ave., Suite 100 94025
- Phone
- (650) 606-7910
- Website
- orukatx.com
- Employees
- 68, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- ORKA
- Exchange
- Nasdaq
- IPO date
- Aug 11, 1997
- Shares outstanding
- 66M, Jul 31, 2026
- Public float
- $371.50M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-12 reverse, Sep 3, 2024; 1-for-18 reverse, May 8, 2019; 1-for-18 reverse, Apr 4, 2019; 1-for-7 reverse, Sep 30, 2015; 1-for-7 reverse, Sep 4, 2015; 1-for-6 reverse, Mar 5, 2013; 1-for-6 reverse, Dec 31, 2012; 1-for-20 reverse, Jan 28, 2009; 1-for-3 reverse, Feb 23, 2004
- SEC CIK
- 907654
- CUSIP
- 687604108
- ISIN
- US6876041087
- LEI
- 529900TG7O4ESUDMGI54
- EIN
- 36-3855489
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lawrence Otto Klein | Chief Executive Officer, Director | 923,128 |
| Paul T. Quinlan | General Counsel | 33,263 |
| Arjun Agarwal | Senior Vice President, Finance | 14,219 |
| Joana Goncalves | Chief Medical Officer | 32,718 |
| Laura Lee Sandler | Chief Operating Officer | 235,478 |
| Larry Todd Edwards | Chief Commercial Officer | 100,000 |
| Healthcare Co-Invest III L.P. Fairmount | Director | – |
| Healthcare Fund II L.P. Fairmount | Director | – |
| Tomas Kiselak | Director | 7,258,672 |
| Funds Management LLC Fairmount | Director | – |
| Peter Evan Harwin | Director | 2,936,922 |
| Carl Dambkowski | Director | 38,743 |
| Christopher Nathan Martin | Director | – |
| Samarth Kulkarni | Director | – |
| Kristine M. Ball | Director | – |
| Cameron Turtle | Director | 85,233 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr Klein | $3.36M | $16.02M | $2.34M | $107 | – |
| FY2024 Dr Bristow | $510.42K | $518.02K | $461.68K | $100 | – |
| FY2024 Dr Klein | $520.91K | $44.70M | $461.68K | $100 | – |
| FY2024 Mr Bristow | $510.42K | – | $461.68K | $100 | – |
| FY2024 Mr Keuer | $853.52K | $848.45K | $461.68K | $100 | – |
| FY2023 Dr Bristow | $358.80K | $290.86K | $361.94K | $72 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“we had 68 full-time employees of which 51 employees were in research and development and the remaining 17 employees worked in”
Corporate history
Events identified from SEC filings